- Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
- Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
- Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
- Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
- Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
- Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
- Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
- Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
- Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
- Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
More ▼
Key statistics
On Friday, Femasys Inc (FEMY:NAQ) closed at 1.27, 412.30% above the 52 week low of 0.2479 set on Sep 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.33 |
---|---|
High | 1.36 |
Low | 1.21 |
Bid | 1.26 |
Offer | 1.31 |
Previous close | 1.33 |
Average volume | 247.96k |
---|---|
Shares outstanding | 22.10m |
Free float | 20.41m |
P/E (TTM) | -- |
Market cap | 28.07m USD |
EPS (TTM) | -0.9396 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼